<?xml version="1.0" encoding="UTF-8"?>
<fig id="F1" orientation="portrait" position="float">
 <label>Figure 1.
  <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml"> </span>
 </label>
 <caption>
  <title>Preparation of viromimetic nanoparticle vaccine and robust humoral and CD4+T cell responses.</title>
  <p>
   <bold>(A)</bold> Schematic representation for the preparation of viromimetic nanoparticle vaccine. Hollow PLGA nanoparticles with encapsulated adjuvant and surface maleimide linkers were prepared using a double emulsion technique. Recombinant viral antigens were then conjugated to the surface of nanoparticles via thiol-maleimide linkage. 
   <bold>(B)</bold> CD4
   <sup>+</sup> T-cell responses against MERS-CoV RBD in immunized mice were determined by intracellular cytokine staining on day 7 after boost, with n = 3 to obtain error bars. 
   <bold>(C)</bold> Frequencies of central memory (CD44
   <sup>+</sup>CD62L
   <sup>+</sup>) CD4
   <sup>+</sup> T cell in the draining lymph nodes of immunized mice 28 days after boosting with n = 3 to obtain error bars. Statistical analyses were performed by unpaired 
   <italic>t</italic>-tests (*p &lt; 0.05). 
   <bold>(D)</bold> MERS-CoV RBD-specific IgG1 and IgG2a titers in immunized mice on day 35 postvaccination with n = 6 to obtain error bars.
  </p>
  <p>CoV: Coronavirus; MERS: Middle East respiratory syndrome; PLGA: Poly(lactide-coglycolide); RBD: Receptor-binding domain.</p>
  <p>Reproduced with permission from [
   <xref rid="B32" ref-type="bibr">32</xref>] © Wiley-VCH Verlag GmbH &amp; Co. KGaA (2019).
  </p>
 </caption>
 <graphic xlink:href="nnm-15-1501-g1" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
